Antibody response to the BNT162b2 SARS-CoV-2 vaccine in paediatric patients with inflammatory bowel disease treated with anti-TNF therapy

Gut. 2022 Sep;71(9):1922-1924. doi: 10.1136/gutjnl-2021-326196. Epub 2021 Nov 23.
No abstract available

Keywords: COVID-19; immune response; inflammatory bowel disease; infliximab; paediatric gastroenterology.

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Viral
  • Antibody Formation
  • BNT162 Vaccine
  • COVID-19 Vaccines
  • COVID-19* / prevention & control
  • Child
  • Humans
  • Inflammatory Bowel Diseases* / drug therapy
  • SARS-CoV-2
  • Tumor Necrosis Factor Inhibitors / therapeutic use

Substances

  • Antibodies, Viral
  • COVID-19 Vaccines
  • Tumor Necrosis Factor Inhibitors
  • BNT162 Vaccine